EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

IEPA, a novel radiation countermeasure, alleviates acute radiation syndrome in rodents

Radoslaw Wesolowski iD, Brian L Fish iD, Michael Eibl iD, Stella Bähr iD, Srishti Munjal Mehta iD, Maciej T Czajkowski iD, Tracy Gasperetti iD, Christie M Orschell iD, Corinna Asang iD, Nikita Singh iD, Heather A Himburg iD, Dirk Pleimes iD

International Journal of Radiation Biology · 2025

DOI: 10.1080/09553002.2024.2425312 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Radiation Biology, 2025. Verfasst von Radoslaw Wesolowski und 11 weiteren Autor:innen. Beteiligte Einrichtung: Myelo Therapeutics GmbH, Berlin, Germany. Hauptthemen laut MEDLINE: Acute Radiation Syndrome, Radiation-Protective Agents, Whole-Body Irradiation, Mice, Inbred C57BL. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NIH/NIAID, Myelo Therapeutics GmbH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Repurposing therapeutic agents with existing clinical data is a common strategy for developing radiation countermeasures. IEPA (imidazolyl ethanamide pentandioic acid) is an orally bioavailable small molecule pseudopeptide with myeloprotective properties, a good clinical safety profile, and stable chemical characteristics facilitating stockpiling. Here, we evaluated IEPA's radiomitigative efficacy in the hematopoietic subsyndrome of acute radiation syndrome (H-ARS) using total-body irradiation (TBI) models in C57BL/6J mice and WAG/RijCmcr rats, applying various posology schemes and introducing syringe feeding of the IEPA formulation in the pudding. Additionally, we assessed IEPA in the delayed effects of acute radiation exposure (DEARE) model after partial-body irradiation (PBI) in WAG/RijCmcr rats. Endpoints included survival, body weight, hematology, and pulmonary parameters, depending on the model. Results from mouse and rat TBI models demonstrated survival improvements with repeated IEPA dosing at 10 mg/kg, with the largest benefits observed in the bi-daily (BID) treatment over the 30-day ARS phase in female rats. Survival across PBI-DEARE subsyndromes was comparable between IEPA and vehicle groups, though IEPA improved pulmonary parameters in female rats during the lung-DEARE phase. Sex-related differences in response to irradiation and IEPA were noted, with females showing a survival advantage. IEPA treatment is compatible with Neulasta® (Pegfilgrastim; PEG-G-CSF); adequately powered studies are needed to confirm the trend toward improved survival over standard care alone. IEPA is a promising development candidate as a medical countermeasure against the effects of acute radiation syndrome. Further confirmatory studies in small and large animal models should validate the robustness and translatability of preliminary rodent data on IEPA's radiomitigative efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Radiation SyndromeRadiation-Protective AgentsWhole-Body IrradiationMice, Inbred C57BLAnimalsFemaleMaleRatsMiceImidazoles

Stichwörter der Autor:innen

Acute radiation syndrome (ARS)IEPA (imidazolyl ethanamide pentandioic acid)radiation countermeasure

Substanzen

Radiation-Protective AgentsImidazoles

Autor:innen und Institutionen

  • Myelo Therapeutics GmbH, Berlin, Germany.
  • Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Department of Medicine/Division of Hematology Oncology, Indiana University School of Medicine, Indianapolis, IN, USA.

ORCID-Profile: Radoslaw Wesolowski, Brian L Fish, Michael Eibl, Stella Bähr, Srishti Munjal Mehta, Maciej T Czajkowski, Tracy Gasperetti, Christie M Orschell, Corinna Asang, Nikita Singh, Heather A Himburg, Dirk Pleimes

Förderung

  • NIAID NIH HHS
  • NIH/NIAID
  • Myelo Therapeutics GmbH

Zitieren

APA

Wesolowski, R., Fish, B. L., Eibl, M., Bähr, S., Munjal Mehta, S., Czajkowski, M. T., Gasperetti, T., Orschell, C. M., Asang, C., Singh, N., Himburg, H. A., & Pleimes, D. (2025). IEPA, a novel radiation countermeasure, alleviates acute radiation syndrome in rodents. International Journal of Radiation Biology. https://doi.org/10.1080/09553002.2024.2425312

Vancouver

Wesolowski R, Fish BL, Eibl M, Bähr S, Munjal Mehta S, Czajkowski MT, et al. IEPA, a novel radiation countermeasure, alleviates acute radiation syndrome in rodents. International Journal of Radiation Biology. 2025. doi:10.1080/09553002.2024.2425312

BibTeX
@article{Wesolowski2025,
  author = {Wesolowski, Radoslaw and Fish, Brian L and Eibl, Michael and Bähr, Stella and Munjal Mehta, Srishti and Czajkowski, Maciej T and Gasperetti, Tracy and Orschell, Christie M and Asang, Corinna and Singh, Nikita and Himburg, Heather A and Pleimes, Dirk},
  title = {IEPA, a novel radiation countermeasure, alleviates acute radiation syndrome in rodents},
  journal = {International Journal of Radiation Biology},
  year = {2025},
  doi = {10.1080/09553002.2024.2425312}
}
Kostenlos starten →